Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Business & Regulation Clinical Trials, Business Practice, Standards & Regulation

Check Out Our Animated Take on the Realities of a "No-deal" Brexit

Back in February we wrote that "hard Brexit looks more likely than ever." Four months later: i) the Withdrawal Agreement (WA) has been rejected in the UK House of Commons for a third time, ii) both candidates for Prime Minister are promising to renegotiate the WA and, if the EU isn’t forthcoming, to leave the EU on October 31 without a deal; and iii) EU leaders are now making it clear that there will be no renegotiation of the WA – and they will not consider another Article 50 extension for the purpose of reopening negotiations on the WA. In short, a hard Brexit appears to be more likely than before.

Our animation covers the basics of how a no-deal Brexit might impact drug developers in the advanced medicines space. For more information, read the full article here.

You can also explore how a no-deal Brexit might impact supply chains.

Enjoy our FREE content!

Log in or register to gain full unlimited access to all content on the The Medicine Maker site. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.

From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register